- Home
- BY vs ETNB Comparison
BY vs ETNB Comparison
Compare BY & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- ETNB
- Stock Information
- Founded
- BY 1914
- ETNB 2018
- Country
- BY United States
- ETNB United States
- Employees
- BY N/A
- ETNB N/A
- Industry
- BY Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- ETNB Health Care
- Exchange
- BY Nasdaq
- ETNB Nasdaq
- Market Cap
- BY 1.1B
- ETNB 1.0B
- IPO Year
- BY 2017
- ETNB 2019
- Fundamental
- Price
- BY $24.18
- ETNB $6.06
- Analyst Decision
- BY Hold
- ETNB Strong Buy
- Analyst Count
- BY 3
- ETNB 10
- Target Price
- BY $33.67
- ETNB $27.56
- AVG Volume (30 Days)
- BY 204.4K
- ETNB 2.5M
- Earning Date
- BY 04-24-2025
- ETNB 05-08-2025
- Dividend Yield
- BY 1.65%
- ETNB N/A
- EPS Growth
- BY 3.00
- ETNB N/A
- EPS
- BY 2.75
- ETNB N/A
- Revenue
- BY $379,856,000.00
- ETNB N/A
- Revenue This Year
- BY $14.42
- ETNB N/A
- Revenue Next Year
- BY $5.03
- ETNB N/A
- P/E Ratio
- BY $8.79
- ETNB N/A
- Revenue Growth
- BY 7.52
- ETNB N/A
- 52 Week Low
- BY $19.82
- ETNB $4.16
- 52 Week High
- BY $32.89
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- BY 39.74
- ETNB 42.57
- Support Level
- BY $22.63
- ETNB $5.68
- Resistance Level
- BY $24.10
- ETNB $6.13
- Average True Range (ATR)
- BY 1.05
- ETNB 0.69
- MACD
- BY -0.02
- ETNB 0.03
- Stochastic Oscillator
- BY 36.73
- ETNB 51.62
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).